AstraZeneca's experimental drug disappoints in breast cancer survival trial

 AstraZeneca (AZN.L) said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo (4568.T) did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.